<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00088816</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000368443</org_study_id>
    <secondary_id>KYUH-UHA-GC03-01</secondary_id>
    <nct_id>NCT00088816</nct_id>
  </id_info>
  <brief_title>S-1 and Cisplatin Before Surgery in Treating Patients With Stage IV Gastric Cancer</brief_title>
  <official_title>Phase II Clinical Study of Preoperative S-1/CDDP Combination Chemotherapy in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as S-1 and cisplatin, work in different ways to
      stop tumor cells from dividing so they stop growing or die. Combining more than one drug may
      kill more tumor cells. Giving combination chemotherapy before surgery may shrink the tumor so
      that it can be removed.

      PURPOSE: This phase II trial is studying how well giving S-1 together with cisplatin works in
      treating patients who are undergoing surgery for stage IV gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the efficacy and feasibility of neoadjuvant chemotherapy comprising S-1 and
           cisplatin in patients with stage IV gastric adenocarcinoma.

        -  Determine the overall survival of patients treated with this regimen.

      Secondary

        -  Determine the time to progression and types of initial recurrence in patients treated
           with this regimen.

        -  Determine tumor response in patients treated with this regimen.

        -  Determine mortality and morbidity related to treatment in these patients.

        -  Determine the toxicity of this regimen in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive oral S-1 on days 1-21 and cisplatin IV over 2 hours on day 8. Treatment
      repeats every 35 days for 2 courses in the absence of disease progression or unacceptable
      toxicity. Patients then undergo gastrectomy with lymphadenectomy. Patients resume oral S-1
      after surgery.

      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2003</start_date>
  <primary_completion_date type="Anticipated">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death related to treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical/pathological curative resection</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Types of initial recurrence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tegafur-gimeracil-oteracil potassium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed gastric adenocarcinoma

               -  Stage IV disease meeting 1 of the following staging criteria according to
                  Japanese gastric cancer classification:

                    -  T4, N2

                    -  T4, N3

                    -  P1, CY1

               -  CT scan and laparoscopic staging required

        PATIENT CHARACTERISTICS:

        Age

          -  20 and over

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC ≥ 4,000/mm^3 AND &lt; 12,000/mm^3

          -  Granulocyte count ≥ 2,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9.0 g/dL

        Hepatic

          -  AST and ALT ≤ 2.5 times upper limit of normal

          -  Bilirubin ≤ 1.5 mg/dL

        Renal

          -  Creatinine clearance ≥ 50 mL/min

        Pulmonary

          -  PaO_2 ≥ 70 mm Hg on room air

        Other

          -  Able to swallow oral medication

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy for gastric cancer

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy for gastric cancer

        Surgery

          -  No prior surgery for gastric cancer

        Other

          -  No other prior therapy for gastric cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seiji Satoh</last_name>
    <role>Study Chair</role>
    <affiliation>Kyoto University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shimane Prefectural Central Hospital</name>
      <address>
        <city>Izumo-shi</city>
        <state>Shimane</state>
        <zip>693-0068</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization - Kyoto Medical Center</name>
      <address>
        <city>Kyoto</city>
        <zip>612-0861</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto-Katsura Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>615-8256</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitano Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>530-8480</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Denryoku Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>553-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamato Municipal Hospital</name>
      <address>
        <city>Yamato City Kanagawa</city>
        <zip>242-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Satoh S, Okabe H, Teramukai S, Hasegawa S, Ozaki N, Ueda S, Tsuji A, Sakabayashi S, Fukushima M, Sakai Y. Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer. Gastric Cancer. 2012 Jan;15(1):61-9. doi: 10.1007/s10120-011-0066-9. Epub 2011 Jun 11.</citation>
    <PMID>21667134</PMID>
  </results_reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

